To consider the role of AusPATH and its position statements on health policy in Australia.
Conclusions
As a consequence of a membership policy which admits members with lived experience as health experts, AusPATH functions as an activist organisation whilst claiming to be a professional association. There is no accreditation or endorsement underpinning AusPATH’s influence on health policy in Australia. Its role as an activist organisation is demonstrated by a lack of caution in its position statements, which are misleading in circumstances where accurate information has been long available. The considerable influence of AusPATH on health policy in Australia needs to be reconsidered, as well as RANZCP Position Statement 62 which provides insufficient guidance upon balancing research and clinical knowledge, as well as medical ethics, with voices of lived experience.
OrszulakDNizińskiKBilA, et al.The effect of gonadoliberin analog treatment in precocious puberty on polycystic ovarian syndrome prevalence in adulthood. Front Endocrinol2024; 15: 1314752.
8.
SolimanAAlaarajNAlyafeiF, et al.2024 Early puberty and abnormal bone health: a comprehensive review. Presented at European Congress of Endocrinology, Stockholm Sweden. Endocr Abstr; 99: EP330.
9.
MulDVersluis-den BiemanHJMSlijperFM, et al.Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr2001; 90(9): 965–971.
10.
De SanctisVSolimanATDi MaioS, et al.Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature. Acta Biomed2019; 90: 345–359.
11.
SolimanATAlaarajNDe SanctisV, et al.Long-term health consequences of central precocious/early puberty (CPP) and treatment with Gn-RH analogue: a short update. Acta Biomed2023; 94(6): e2023222.
Delemarre-van de WaalHACohen-KettenisPT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol2006; 155(Issue Supplement 1): S131–S137.
14.
StaphorsiusASKreukelsBPCohen-KettenisPT, et al.Puberty suppression and executive functioning: an fMRI-study in adolescents with gender dysphoria. Psychoneuroendocrinology2015; 56: 190–199.
15.
HoughDBellinghamMHaraldsenIRH, et al.Spatial memory is impaired by peripubertal GnRH agonist treatment and testosterone replacement in sheep. Psychoneuroendocrinology2017; 75: 173–182.
GoorenLDelemarre-van de WaalH. The feasibility of endocrine interventions in juvenile transsexuals. J Psychol Hum Sex1996; 8: 69–74.
18.
KlinkDCarisMHeijboerA, et al.Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab2015; 100(2): E270–E275.
19.
SchagenSEEWoutersFMCohen-KettenisPT, et al.Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones. J Clin Endocrinol Metab2020; 105(12): e4252–e4263.
20.
CarmichaelPButlerGMasicU, et al.Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLoS One2021; 16(2): e0243894.
MurugeshVRittingMSalemS, et al. (2024) Puberty blocker and aging impact on testicular cell states and function. bioRxiv586441. doi: 10.1101/2024.03.23.586441.
23.
HembreeWCCohen-KettenisPTGoorenL, et al.Endocrine treatment of genderdysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2017; 102(11): 3869–3903.
LeeJYRosenthalSM. Gender-affirming care of transgender and gender-diverse youth: current concepts. Annu Rev Med2023; 74: 107–116. DOI: 10.1146/annurev-med-043021-032007.
